Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Marsha Reyngold

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9475-146X; OpenAlex author ID A5052448371, A5158598680. Sources: ClinicalTrials.gov.

Their work

Papers
29 (first author 3, last author 2)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
168
Papers, trials and grants by year

2015: 1 trial · 2016: none · 2017: 1 paper · 2018: 1 trial · 2019: 2 papers · 2020: 2 papers · 2021: 6 papers, 1 trial · 2022: 4 papers · 2023: 1 paper · 2024: 1 paper · 2025: 5 papers · 2026: 7 papers

Papers 29

  1. Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer: A Nonrandomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2026.2988↗
  2. Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline. Co-author DOI 10.1016/j.prro.2026.07.002↗
  3. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Co-author DOI 10.1038/s41591-026-04299-5↗
  4. Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-24-0772↗
  5. Pancreatic Cancer: Translating Tumor Biology into Actionability. Co-author DOI 10.1158/2159-8290.cd-25-2014↗
  6. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  7. Neoantigen-reactive CD8 + T cell engagement marks exceptional survivors of pancreatic cancer Co-author DOI 10.64898/2026.09.17.752426↗
  8. Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy. Co-author DOI 10.1001/jamaoncol.2025.0460↗
  9. Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5191↗
  10. NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy. Co-author DOI 10.1016/j.ijrobp.2024.10.026↗
  11. Outcomes in Locally Advanced Pancreatic Cancer After Induction Ablative Radiation Therapy and Resection. Co-author DOI 10.1245/s10434-025-17199-8↗
  12. Multi-Institutional Comparison of Ablative 5-Fraction Magnetic Resonance-Guided Online Adaptive Versus 15/25-Fraction Computed Tomography-Guided Moderately Hyp… Last author DOI 10.3390/cancers17152596↗
  13. Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery. Last author DOI 10.3390/jcm13092631↗
  14. Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2023.03.036↗
  15. Automatic stent recognition using perceptual attention U-net for quantitative intrafraction motion monitoring in pancreatic cancer radiotherapy. Co-author DOI 10.1002/mp.15692↗
  16. Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system. Co-author DOI 10.1016/j.phro.2022.10.003↗
  17. CT and cone-beam CT of ablative radiation therapy for pancreatic cancer with expert organ-at-risk contours. First author DOI 10.1038/s41597-022-01758-9↗
  18. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. Co-author DOI 10.6004/jnccn.2022.7008↗
  19. Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. Co-author DOI 10.1001/jamaoncol.2021.0057↗
  20. Accuracy and efficiency of respiratory gating comparable to deep inspiration breath hold for pancreatic cancer treatment. Co-author DOI 10.1002/acm2.13137↗
  21. Deep-learning-based image registration and automatic segmentation of organs-at-risk in cone-beam CT scans from high-dose radiation treatment of pancreatic canc… Co-author DOI 10.1002/mp.14906↗
  22. Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. First author DOI 10.1097/sla.0000000000005080↗
  23. Longitudinal Monitoring of Simulated Interstitial Fluid Pressure for Pancreatic Ductal Adenocarcinoma Patients Treated with Stereotactic Body Radiotherapy. Co-author DOI 10.3390/cancers13174319↗
  24. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  25. Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704. Co-author DOI 10.1634/theoncologist.2019-0562↗
  26. Diffusion-Weighted and Dynamic Contrast-Enhanced MRI Derived Imaging Metrics for Stereotactic Body Radiotherapy of Pancreatic Ductal Adenocarcinoma: Preliminar… First author DOI 10.18383/j.tom.2020.00015↗
  27. Intrafraction tumor motion during deep inspiration breath hold pancreatic cancer treatment. Co-author DOI 10.1002/acm2.12577↗
  28. Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results. Co-author DOI 10.1186/s13014-019-1309-x↗
  29. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. Co-author DOI 10.1080/0284186x.2017.1342863↗

Trials 3

  1. Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer with Homologous Recombination Deficiency That Has Spread to the Liver Principal investigator NCT05182112↗
  2. Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer Principal investigator NCT03523312↗
  3. A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer Principal investigator NCT02643498↗

Closest collaborators

The 25 strongest of 168 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christopher H. Crane · 16 shared papers, 2017–2026 · strength 2.50
  2. Eileen Mary O'Reilly · 13 shared papers, 2017–2026 · strength 2.25
  3. Wungki Park · 8 shared papers, 2021–2026 · strength 1.43
  4. Carla Hajj · 9 shared papers, 2017–2026 · strength 1.37
  5. Kenneth H. Yu · 9 shared papers, 2017–2026 · strength 1.32
  6. Alice Chia-Chi Wei · 7 shared papers, 2021–2026 · strength 1.22
  7. Kevin C. Soares · 5 shared papers, 2021–2026 · strength 1.04
  8. Abraham Jing-Ching Wu · 7 shared papers, 2017–2025 · strength 1.03
  9. Karyn A. Goodman · 7 shared papers, 2017–2026 · strength 1.03
  10. Anna M. Varghese · 6 shared papers, 2021–2026 · strength 0.94
  11. William R. Jarnagin · 5 shared papers, 2021–2026 · strength 0.85
  12. Danny N. Khalil · 5 shared papers, 2021–2026 · strength 0.84
  13. Christine A. Iacobuzio–Donahue · 3 shared papers, 2026 · strength 0.76
  14. Vinod P. Balachandran · 4 shared papers, 2021–2026 · strength 0.74
  15. Jeffrey A. Drebin · 4 shared papers, 2021–2026 · strength 0.72
  16. Fiyinfolu O. Balogun · 3 shared papers, 2026 · strength 0.70
  17. Amol Kumar Narang · 4 shared papers, 2021–2026 · strength 0.68
  18. Michael David Chuong · 3 shared papers, 2025–2026 · strength 0.61
  19. Michael Ian D'Angelica · 3 shared papers, 2021–2026 · strength 0.55
  20. Zhigang Zhang · 4 shared papers, 2017–2025 · strength 0.52
  21. Mara H. Sherman · 2 shared papers, 2026 · strength 0.49
  22. Andrew H. Ko · 3 shared papers, 2021–2026 · strength 0.42
  23. Vincent M. Chung · 3 shared papers, 2021–2026 · strength 0.42
  24. Michael Frederick Bassetti · 2 shared papers, 2025–2026 · strength 0.41
  25. Nina Niu Sanford · 2 shared papers, 2025–2026 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.